SKBA Capital Management’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $775K | Sell |
3,930
-1
| -0% | -$193 | 0.11% | 60 |
|
|
2025
Q4 | $723K | Sell |
3,931
-15
| -0.4% | -$2.63K | 0.1% | 69 |
|
|
2025
Q3 | $605K | Buy |
3,946
+250
| +7% | +$37.8K | 0.08% | 71 |
|
|
2025
Q2 | $516K | Buy |
3,696
+1,150
| +45% | +$161K | 0.07% | 71 |
|
|
2025
Q1 | $374K | Buy |
+2,546
| New | +$368K | 0.06% | 74 |
|
|
2023
Q4 | – | Sell |
-36,768
| Closed | -$4.98M | – | 77 |
|
|
2023
Q3 | $4.98M | Hold |
36,768
| – | – | 0.92% | 48 |
|
|
2023
Q2 | $5.26M | Sell |
36,768
-200
| -0.5% | -$29.4K | 0.95% | 48 |
|
|
2023
Q1 | $5.13M | Sell |
36,968
-517
| -1% | -$69.6K | 0.96% | 51 |
|
|
2022
Q4 | $5.08M | Sell |
37,485
-218
| -0.6% | -$27.3K | 0.94% | 48 |
|
|
2022
Q3 | $4.13M | Sell |
37,703
-82
| -0.2% | -$10.4K | 0.88% | 49 |
|
|
2022
Q2 | $4.99M | Sell |
37,785
-22,450
| -37% | -$2.95M | 1% | 47 |
|
|
2022
Q1 | $7.99M | Sell |
60,235
-550
| -0.9% | -$66K | 1.44% | 38 |
|
|
2021
Q4 | $7.08M | Sell |
60,785
-250
| -0.4% | -$29.4K | 1.33% | 41 |
|
|
2021
Q3 | $7.33M | Hold |
61,035
| – | – | 1.46% | 33 |
|
|
2021
Q2 | $7.31M | Sell |
61,035
-29,100
| -32% | -$3.19M | 1.43% | 37 |
|
|
2021
Q1 | $8.96M | Buy |
90,135
+41,200
| +84% | +$4.14M | 1.42% | 41 |
|
|
2020
Q4 | $4.89M | Sell |
48,935
-22,350
| -31% | -$2.37M | 0.82% | 54 |
|
|
2020
Q3 | $7.81M | Sell |
71,285
-4,700
| -6% | -$523K | 1.56% | 29 |
|
|
2020
Q2 | $8.04M | Sell |
75,985
-800
| -1% | -$82.6K | 1.56% | 34 |
|
|
2020
Q1 | $6.86M | Sell |
76,785
-30,900
| -29% | -$2.91M | 1.56% | 33 |
|
|
2019
Q4 | $10.7M | Sell |
107,685
-8,150
| -7% | -$767K | 1.7% | 30 |
|
|
2019
Q3 | $10.3M | Sell |
115,835
-350
| -0.3% | -$30.3K | 1.64% | 29 |
|
|
2019
Q2 | $9.59M | Sell |
116,185
-4,900
| -4% | -$384K | 1.53% | 31 |
|
|
2019
Q1 | $9.79M | Sell |
121,085
-12,050
| -9% | -$950K | 1.57% | 36 |
|
|
2018
Q4 | $10.1M | Sell |
133,135
-9,700
| -7% | -$757K | 1.64% | 33 |
|
|
2018
Q3 | $11.3M | Buy |
142,835
+32,500
| +29% | +$2.46M | 1.47% | 36 |
|
|
2018
Q2 | $7.75M | Sell |
110,335
-1,950
| -2% | -$140K | 1.05% | 44 |
|
|
2018
Q1 | $7.85M | Sell |
112,285
-250
| -0.2% | -$17.3K | 1.06% | 44 |
|
|
2017
Q4 | $7.81M | Sell |
112,535
-50
| -0% | -$3.37K | 1.09% | 40 |
|
|
2017
Q3 | $7.63M | Buy |
112,585
+17,800
| +19% | +$1.12M | 1.1% | 41 |
|
|
2017
Q2 | $6.46M | Buy |
+94,785
| New | +$6.19M | 0.98% | 47 |
|
Other funds holding AZN
IA
VCM
VAM
SKBA Capital Management's AZN Position: Q1 2026 in Review
SKBA Capital Management reduced its AstraZeneca (AZN) stake by 0.03% in Q1 2026, selling an estimated $193 and leaving 3,930 shares worth $775K. The position accounts for 0.11% of the portfolio, ranked #60.
SKBA Capital Management first reported a position in AZN in Q2 2017 and has held it in 31 quarters since. The position peaked at $11.3M in Q3 2018. 1,379 funds tracked by Wall St. Rank hold AZN as of Q1 2026.
- SKBA Capital Management held 3,930 shares of AstraZeneca worth $775K as of Q1 2026.
- SKBA Capital Management sold 1 AstraZeneca share in Q1 2026, an estimated $193.
- AstraZeneca made up 0.11% of SKBA Capital Management's portfolio in Q1 2026, its #60 holding.
- SKBA Capital Management first reported a position in AstraZeneca in Q2 2017 and has held it in 31 quarters since.
- SKBA Capital Management's AstraZeneca position peaked at $11.3M in Q3 2018.
- 1,379 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.
Based on SKBA Capital Management's 13F filing for Q1 2026, filed 13 May 2026.